Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 3
1999 4
2000 2
2001 3
2002 1
2003 2
2004 3
2009 1
2010 2
2011 3
2013 4
2014 2
2015 2
2016 1
2017 1
2018 2
2020 1
2021 5
2022 7
2023 3
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Genomic Profiling of Highly Aggressive Musculoskeletal Sarcomas Identifies Potential Therapeutic Targets: A Single-Center Experience.
Parra A, Palmerini E, Laginestra MA, Ferrari C, Cocchi S, Simonetti E, Pellegrini E, De Feo A, Magagnoli G, Frega G, Donati DM, Gambarotti M, Ibrahim T, Scotlandi K, Landuzzi L, Pazzaglia L. Parra A, et al. Among authors: magagnoli g. Cancers (Basel). 2025 Dec 31;18(1):139. doi: 10.3390/cancers18010139. Cancers (Basel). 2025. PMID: 41514647 Free PMC article.
We report on TGS real-world data over a period of 3 years (2022-2025) at the IRCCS Istituto Ortopedico Rizzoli, with the aim of identifying potential actionable targets and providing therapeutic indications for advanced sarcoma patients. ...
We report on TGS real-world data over a period of 3 years (2022-2025) at the IRCCS Istituto Ortopedico Rizzoli, with the aim of ident …
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
Zając AE, Rutkowski P, Szumera-Ciećkiewicz A, Piątkowski J, Teterycz P, Palmerini E, Dutour A, Tuziak-Klym J, Wągrodzki M, Pieńkowski A, Tysarowski A, Gambarotti M, Frega G, Pierini M, Righi A, Magagnoli G, Jean-Denis M, Ibrahim T, Blay JY, Golik P, Czarnecka AM. Zając AE, et al. Among authors: magagnoli g. Int J Mol Sci. 2026 Feb 20;27(4):2018. doi: 10.3390/ijms27042018. Int J Mol Sci. 2026. PMID: 41752158 Free PMC article.
Primary synovial sarcoma of bone: a retrospective analysis of 25 patients.
Righi A, Gambarotti M, Benini S, Gibertoni D, Asioli S, Magagnoli G, Gamberi G, Sbaraglia M, Cocchi S, Staals E, Palmerini E, Dei Tos AP. Righi A, et al. Among authors: magagnoli g. Histopathology. 2022 Mar;80(4):686-697. doi: 10.1111/his.14602. Epub 2022 Jan 18. Histopathology. 2022. PMID: 34821406
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.
Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M. Tavanti E, et al. Among authors: magagnoli g. Br J Cancer. 2013 Nov 12;109(10):2607-18. doi: 10.1038/bjc.2013.643. Epub 2013 Oct 15. Br J Cancer. 2013. PMID: 24129234 Free PMC article.
Altered G1 phase regulation in osteosarcoma.
Benassi MS, Molendini L, Gamberi G, Sollazzo MR, Ragazzini P, Merli M, Magagnoli G, Sangiorgi L, Bacchini P, Bertoni F, Picci P. Benassi MS, et al. Among authors: magagnoli g. Int J Cancer. 1997 Oct 21;74(5):518-22. doi: 10.1002/(sici)1097-0215(19971021)74:5<518::aid-ijc7>3.0.co;2-6. Int J Cancer. 1997. PMID: 9355974
55 results